Insider Transaction Details
On April 21, 2026, Vincent S. LoPriore, who serves as Executive Chairman and Director at Hepion Pharmaceuticals (NASDAQ:HEPA), expanded his stake in the company through a $250,000 purchase of common stock. The shares were acquired at a rate of $0.04 per share, resulting in an indirect acquisition of 6,250,000 shares total.
The structure of these purchases involves two separate indirect holdings:
- Gravitas Capital LP: This entity acquired 5,000,000 shares. Mr. LoPriore holds the role of Managing Member for Gravitas Capital LP, providing him with the power to vote and dispose of the securities held by the firm.
- Invictus Capital Advisors Pension Plan: This plan acquired 1,250,000 shares. As the trustee and beneficiary of this pension plan, Mr. LoPriore retains the rights to vote and dispose of these holdings.
Following these moves, Mr. LoPriore's reported indirect interest in Hepion Pharmaceuticals stands at 6,250,000 shares. From a balance sheet perspective, data indicates that Hepion Pharmaceuticals maintains a position where its cash holdings exceed its total debt.
Leadership Transitions and Separation Terms
The insider activity follows the announcement of Dr. Kaouthar Lbiati's resignation as CEO of Hepion Pharmaceuticals. Dr. Lbiati cited personal reasons for her decision to step down. A formal separation agreement has been established between the company and the former executive, according to recent SEC filings.
Under the specific terms of this separation agreement:
- Dr. Lbiati will receive a payment of $225,000.
- A pro-rata cash bonus of $30,625 is included in the package.
- The company will provide reimbursement for COBRA health insurance payments for a period of six months.
- As part of the exit terms, Dr. Lbiati has agreed to confidentiality and a general release.
These leadership changes are occurring amidst broader organizational shifts within the company's structure. It is important to note that the recent announcements have not provided updates regarding the company's revenue or earnings results, nor has analyst feedback concerning future expectations been released.
Market Context and Performance
The timing of this $250,000 purchase is notable given the stock's recent volatility. While HEPA shares have seen a 12.6% increase over the last week, the long-term trend shows a decline of 85.7% over the past year. Investors and market participants are likely to keep a close watch on any further disclosures regarding the company's strategic direction or upcoming leadership appointments.